Budoucí P/E společnosti Amgen
Jaká je hodnota metriky Budoucí P/E společnosti Amgen?
Hodnota metriky Budoucí P/E společnosti Amgen, Inc. je 15.20
Jaká je definice metriky Budoucí P/E?
Budoucí poměr P/E (Forward price to earnings ratio) vyjadřuje poměr současné ceny a odhadovaného zisku na akcii v následujících dvanácti měsících.
The forward price to earnings ratio is similar to trailing price to earnings ratio but instead of net income uses estimated net earnings over next 12 months. Estimates are typically derived as the mean of those published by a select group of analysts with selection criteria varying. The forward price-to-earnings ratio is a powerful, but limited tool. It allows a quick snapshot of the company’s finances without getting down in the details of an accounting report.
Budoucí P/E společností v sektoru Health Care sektor na XETRA ve srovnání se společností Amgen
Čemu se věnuje společnost Amgen?
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Firmy s metrikou budoucí p/e podobnou společnosti Amgen
- Hodnota metriky Budoucí P/E společnosti Premium Brands je 15.17
- Hodnota metriky Budoucí P/E společnosti Boiron SA je 15.17
- Hodnota metriky Budoucí P/E společnosti Mirvac Stapled Securities je 15.17
- Hodnota metriky Budoucí P/E společnosti Rank Plc je 15.17
- Hodnota metriky Budoucí P/E společnosti Assured Guaranty Ltd je 15.18
- Hodnota metriky Budoucí P/E společnosti Canadian National Railway Co je 15.18
- Hodnota metriky Budoucí P/E společnosti Amgen je 15.20
- Hodnota metriky Budoucí P/E společnosti Texas Pacific Land je 15.22
- Hodnota metriky Budoucí P/E společnosti Indoco Remedies je 15.22
- Hodnota metriky Budoucí P/E společnosti Evolution Mining je 15.22
- Hodnota metriky Budoucí P/E společnosti Parker-Hannifin je 15.22
- Hodnota metriky Budoucí P/E společnosti Ashtead Plc je 15.22
- Hodnota metriky Budoucí P/E společnosti Iberdrola SA je 15.22